2010   Print Screen
 
 

QuantRx to Present at OneMedForum 2010 Finance Conference

 

Presentation to Highlight Company’s Key Platform Comprised of Q-Reader™ Point-of-care Diagnostic Reader Device and Proprietary Lateral Flow Technology

 

 

DOYLESTOWN, PA – January 11, 2010 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today that Walter Witoshkin, Chairman and Chief Executive Officer, will present at the OneMedForum 2010 Emerging Company Finance Conference in San Francisco, CA, on Wednesday, January 13, 2010.

The annual OneMedForum conference connects emerging healthcare and life science companies with investors and strategic partners. The focus for this year’s event is DEVICES AND THERAPEUTICS - Companies Shaping the Future of Health and Medicine.  A key theme at the conference will be Diagnostics & Personalized Medicine. This topic will explore the changing world of diagnostics, focusing on the product areas and business models that have made this such a hot area for investors. 

Mr. Witoshkin will discuss for conference attendees QuantRx’s key medical technology platform comprised of its Q-Reader™ point-of-care diagnostic reader device and proprietary lateral flow technology.  As the Company’s most important near term product in development which has a multi-billion dollar addressable market, the new flagship point-of-care diagnostic reader device actually defines the level of metabolic markers as a front line tool for point-of-care, rather than necessitating the delayed process of third party clinical laboratory testing. 

About the OneMedForum 2010 Conference and OneMedPlace

 

Held annually in San Francisco, the OneMedForum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world.  The conference’s unique format of sector-oriented panel discussions, company presentations and investor meetings is designed to connect CEOs with appropriate institutional, venture and private investors.

OneMedPlace (OMP), the organizer of the OneMedForum, is a virtual community for those involved in bringing innovation to the market. It is one place to find the latest innovations in health and medicine and a portal to access the best information available for strategic and financial investors.  Anchored by a database of over 7,000 companies, OMP provides an integrated set of research and multi-media communications tools which facilitate communications among those building the companies shaping the future of health and medicine.

 

About QuantRx Biomedical

QuantRx Biomedical Corporation (OTCBB: QTXB) is a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by healthcare professionals and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care.

The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than three dozen patents, patents pending and licensed patents, includes: (1) RapidSense® and Q-Reader™ point-of-care testing products based on QuantRx core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets (QN Diagnostics); (2) PAD technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs, and (3) significant investments in: (a) genome-based diagnostic chips for the laboratory and healthcare professional markets; and (b) molecular imaging agents for positron emission tomography (PET) and fluorescence imaging, with initial application in cardiovascular disease, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.

Additional information on QuantRx is available at www.quantrx.com.

# # #

Forward Looking Statements Disclaimer for QuantRx Biomedical Corporation: This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company’s need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

* * *

 

 

Investor Relations Contact:

Jordan M. Darrow

Darrow Associates, Inc.

631-367-1866

jdarrow@darrowir.com

 

  

 


© Copyright 2007 - QuantRx® Biomedical Corporation